Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 5:16:1049-1053.
doi: 10.2147/IJWH.S431520. eCollection 2024.

Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection

Giulia Marchetti  1 , Annika Taithongchai  2 , Dudley Robinson  2
Affiliations
Review

Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection

Giulia Marchetti et al. Int J Womens Health. .

Abstract

Vulvar vaginal atrophy is a common condition affecting postmenopausal women, significantly impacting their quality of life. Fortunately, various treatment options are available, ranging from hormonal to non-hormonal therapies. Ospemifene has emerged as a promising non-hormonal alternative for managing vulvar vaginal atrophy. Its targeted approach, unique mechanism of action, favorable safety profile particularly for breast tissue, and efficacy make it a valuable option for women seeking relief from symptoms such as vaginal pain, dryness and dyspareunia and cannot receive estrogen supplementations. This is particularly the case for breast cancer survivors or women with a significant family history of estrogen-dependent cancers. Hence, tailored treatment plans, considering individual preferences and health circumstances, are essential in optimizing outcomes and improving the overall well-being of affected individuals.

Keywords: breast cancer; detrusor overactivity; genitourinary syndrome of menopause; ospemifene; vulvovaginal atrophy.

PubMed Disclaimer

Conflict of interest statement

Dr Dudley Robinson reports personal fees from Astellas, personal fees from AbbVie, personal fees from Pierre Fabre, during the conduct of the study. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

References

    1. Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61:508–516. doi:10.1097/GRF.0000000000000380 - DOI - PubMed
    1. Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Climacteric. 2014;17(5):557–563. doi:10.3109/13697137.2014.946279 - DOI - PubMed
    1. ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93–6. doi:10.1097/AOG.0000000000001351 - DOI - PubMed
    1. Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2021;191:269–275. doi:10.1007/s10549-021-06436-9 - DOI - PubMed
    1. Kingsberg SA. Vaginal health and lubricants. Post Reprod Health. 2016;22(4):171–172.